Genetic Systems technology purchase
Executive Summary
Firm purchased from Cutter all rights to its Phase/research program for the production of therapeutic human monocional antibodies for hospital-acquired infections from gram negative bacteria. Two firms had previously agreed to undertake the research in October 1983. Under a separate agreement with the Cutter Group, Genetic Systems is developing human monoclonal antibodies to pseudomonas bacteria. Antibodies have bean transferred to Cutter for scale-up and clinical trials. Genetic Systems said it will receive a royalty on all saies of products for pseudomonas infections.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.